Drugs / Sintlimab
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06742502 | Nov 2024 → Dec 2027 expected | primary mediastinal large B-cell lymphoma | Sun Yat-sen University | Recruiting | No outcome recorded |
| Phase 2 | NCT06364384 | Apr 2024 → Sep 2026 expected | squamous cell carcinoma of rectum | Sixth Affiliated Hospital, Sun Yat-sen University | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Sintlimab | “PD-1 monoclonal antibody(sintlimab) 200mg, d1, intravenous infusion” NCT06364384 ↗ |
| Modality | Monoclonal antibody | “PD-1 monoclonal antibody(sintlimab)” NCT06364384 ↗ |
| Route | Intravenous | “sintlimab) 200mg, d1, intravenous infusion” NCT06364384 ↗ |